Comparing blood versus tissue-based biomarkers expression in breast cancer patients

Oloomi, Mana; Moazzezy, Neda; Bouzari, Saeid

doi:10.1016/j.heliyon.2020.e03728

Cited by 24 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biomarkers for immunotherapy patient selection and prognosis prediction were not able to follow the speed and success of drug development and indication expansions [ 33 ]. Most candidate biomarkers involve tumor molecular characteristics and are subject to several limitations, including the one-dimensional nature, need for biopsy, and cost issues [ 34 , 35 ]. The compound prognostic scores based on simple clinical and laboratory parameters have recently gained significant interest for prognosis prediction in ICI-treated patients [ 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

Güven

Şahin

Erul

et al. 2022

JCM

View full text Add to dashboard Cite

Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited. We evaluated the association between the neutrophil–lymphocyte ratio (NLR) and early NLR changes with survival in ICI-treated patients. We retrospectively evaluated the data of 231 patients with advanced-stage cancer. We recorded baseline clinical characteristics, baseline NLR and fourth-week NLR changes, and survival data. A compound prognostic score, the NLR2-CEL score, was developed with the following parameters: baseline NLR (<5 vs. ≥5), ECOG status (0 vs. ≥1), Charlson Comorbidity Index (CCI, <9 vs. ≥9), and fourth-week NLR change (10% or over NLR increase). In the multivariable analyses, higher NLR (HR: 1.743, p = 0.002), 10% or over NLR increase in the fourth week of treatment (HR: 1.807, p = 0.001), higher ECOG performance score (HR: 1.552, p = 0.006), higher LDH levels (HR: 1.454, p = 0.017), and higher CCI (HR: 1.400, p = 0.041) were associated with decreased OS. Compared to patients with the lowest scores, patients in the highest score group had significantly lower OS (HR: 7.967, 95% CI: 3.531–17.979, p < 0.001) and PFS. The composite score had moderate success for survival prediction, with an AUC of 0.702 (95% CI: 0.626–0.779, p < 0.001). We observed significantly lower survival in patients with higher baseline NLR values and increased NLR values under treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

Güven

Şahin

Erul

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Therefore, these unexpected results are probably due to systemic αKlotho possibly not representing the local production of Klotho. Other publications have already demonstrated that biomarkers such as carcinoembryonic antigen, ERβ, cytokeratin 19 and c-Myc present in serum do not represent the production in a tumor microenvironment ( 77 ).…”

Section: Discussionmentioning

confidence: 99%

Undetected αKlotho in serum is associated with the most aggressive phenotype of breast cancer

et al. 2022

View full text Add to dashboard Cite

Klotho, a cellular anti-senescence protein, is related to antitumor actions, growth regulation, proliferation and invasiveness in several types of tumor, including breast cancer. The present study aimed to analyze the serum levels of αKlotho in patients with breast cancer according to histopathological and immunohistochemical variables. A total of 74 patients and 60 healthy controls were recruited. Peripheral blood samples were collected and serum levels were assessed by sandwich ELISA. Clinical and diagnostic data were obtained from medical records and databases of the Clinical Hospital of the Federal University of Uberlândia (Uberlândia, Brazil). The results indicated no difference in the levels of αKlotho between patients and controls (P=0.068); however, the number of patients with breast cancer with undetectable αKlotho was high (n=52). Thus, the variables that were associated with the lowest survival rates were analyzed, relating them to undetectable αKlotho. Among cases of metastatic tumors or tumors with poor differentiation, positive lymph node status and triple-negative status, patients with undetectable αKlotho predominated and had unfavorable overall survival. Due to the significant results obtained in triple-negative patients, an in vitro analysis was performed to determine whether estrogen receptors (ERs) have a role in αKlotho production. Treatment of MCF-7 cells with ER agonists, estradiol (E2) and diarylpropionitrile (DPN), resulted in increases in αKlotho expression and supernatant levels of both agonists, demonstrating a direct association between the ER and Klotho production; of note, the ERβ-specific agonist DPN tripled αKlotho expression when compared to E2 (P=0.078). These data suggested that undetectable αKlotho in the serum of patients with breast cancer is related to unfavorable histopathological variables and poor prognosis and ERs possibly have an important role in maintaining adequate quantities of αKlotho.

show abstract

“…Whole blood collection is a non-invasive procedure and has been used for supporting diagnostics and/or monitoring circulating biomarkers. For instance; cancer antigen 125 (CA-125) for ovarian cancer [ 40 ]; CA-11-19 for colorectal cancer [ 41 ], CA-19-9 for lung cancer [ 42 ], and CA-15-3 for breast cancer [ 43 ], are well established markers in clinical practice. Circulating tumor DNA (ctDNA), tumor-derived cell-free DNA, may be promising in diagnosis of cancer and/or monitoring of relapse or progression [ 44 ].…”

Section: Precautions Of Data Output From Sequencingmentioning

confidence: 99%

Next Generation Sequencing Technology in the Clinic and Its Challenges

Vestergaard

Oliveira

Høgdall

et al. 2021

Cancers

View full text Add to dashboard Cite

Data analysis has become a crucial aspect in clinical oncology to interpret output from next-generation sequencing-based testing. NGS being able to resolve billions of sequencing reactions in a few days has consequently increased the demand for tools to handle and analyze such large data sets. Many tools have been developed since the advent of NGS, featuring their own peculiarities. Increased awareness when interpreting alterations in the genome is therefore of utmost importance, as the same data using different tools can provide diverse outcomes. Hence, it is crucial to evaluate and validate bioinformatic pipelines in clinical settings. Moreover, personalized medicine implies treatment targeting efficacy of biological drugs for specific genomic alterations. Here, we focused on different sequencing technologies, features underlying the genome complexity, and bioinformatic tools that can impact the final annotation. Additionally, we discuss the clinical demand and design for implementing NGS.

show abstract

Comparing blood versus tissue-based biomarkers expression in breast cancer patients

Cited by 24 publications

References 28 publications

The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

Undetected αKlotho in serum is associated with the most aggressive phenotype of breast cancer

Next Generation Sequencing Technology in the Clinic and Its Challenges

Contact Info

Product

Resources

About